These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21099599)

  • 1. Common abnormal results of pap and human papillomavirus cotesting: what physicians are recommending for management.
    Berkowitz Z; Saraiya M; Benard V; Yabroff KR
    Obstet Gynecol; 2010 Dec; 116(6):1332-1340. PubMed ID: 21099599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination.
    Malo TL; Perkins RB; Lee JH; Vadaparampil ST
    Sex Transm Dis; 2016 Jul; 43(7):438-44. PubMed ID: 27322046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers.
    Lee JW; Berkowitz Z; Saraiya M
    Obstet Gynecol; 2011 Jul; 118(1):4-13. PubMed ID: 21691157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States.
    Irwin K; Montaño D; Kasprzyk D; Carlin L; Freeman C; Barnes R; Jain N; Christian J; Wolters C
    Obstet Gynecol; 2006 Aug; 108(2):397-409. PubMed ID: 16880312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Papillomavirus Testing by Veterans Administration Women's Health Providers: Are They Adhering to Guidelines?
    Hallett LD; Gerber MR
    J Womens Health (Larchmt); 2018 Feb; 27(2):179-182. PubMed ID: 28885082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.
    Saraiya M; Benard VB; Greek AA; Steinau M; Patel S; Massad LS; Sawaya GF; Unger ER
    Am J Obstet Gynecol; 2014 Oct; 211(4):354.e1-6. PubMed ID: 24813971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19-26year old females.
    Hirth JM; Lin YL; Kuo YF; Berenson AB
    Prev Med; 2016 Jul; 88():134-9. PubMed ID: 27085993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.
    Castle PE; Wacholder S; Sherman ME; Lorincz AT; Glass AG; Scott DR; Rush BB; Demuth F; Schiffman M
    Cancer; 2002 Nov; 95(10):2145-51. PubMed ID: 12412168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
    Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
    J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age.
    Lin CT; Tseng CJ; Lai CH; Hsueh S; Huang HJ; Law KS
    J Reprod Med; 2000 Apr; 45(4):345-50. PubMed ID: 10804494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
    Wong AK; Chan RC; Nichols WS; Bose S
    Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated With Guideline-concordant and Excessive Cervical Cancer Screening: A Mixed Methods Study.
    Perkins RB; Fuzzell L; Lake P; Brownstein NC; Fontenot HB; Michel A; Whitmer A; Vadaparampil ST
    Womens Health Issues; 2024; 34(3):257-267. PubMed ID: 38383228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007.
    Yabroff KR; Saraiya M; Meissner HI; Haggstrom DA; Wideroff L; Yuan G; Berkowitz Z; Davis WW; Benard VB; Coughlin SS
    Ann Intern Med; 2009 Nov; 151(9):602-11. PubMed ID: 19884621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
    Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
    Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.